{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:48:10Z","timestamp":1776959290587,"version":"3.51.4"},"reference-count":9,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,23]]},"DOI":"10.1182\/blood.2026033164","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:31:47Z","timestamp":1776958307000},"page":"1889-1891","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Donor T cells on double duty: VCAR33 for AML after transplant"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-9117","authenticated-orcid":false,"given":"Mark B.","family":"Geyer","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"17","key":"2026042311314055900_bib1","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1182\/blood.2025031053","article-title":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT","volume":"147","author":"Mushtaq","year":"2026","journal-title":"Blood"},{"issue":"11","key":"2026042311314055900_bib2","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"key":"2026042311314055900_bib3","doi-asserted-by":"crossref","first-page":"e2500556","DOI":"10.1200\/PO-25-00556","article-title":"Remission of TP53-mutant AML after transplantation with trem-cel, a CRISPR\/Cas9 gene-edited allograft lacking CD33, followed by a donor-derived anti-CD33 chimeric antigen receptor T (VCAR33)","volume":"9","author":"Koehne","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"suppl 1","key":"2026042311314055900_bib4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2023-179667","article-title":"CD33 CAR T-cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial [abstract]","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026042311314055900_bib5","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"2026042311314055900_bib6","doi-asserted-by":"crossref","first-page":"780442","DOI":"10.3389\/fimmu.2021.780442","article-title":"T cell fitness and autologous CAR T cell therapy in haematologic malignancy","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Immunol"},{"issue":"26","key":"2026042311314055900_bib7","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.2025029532","article-title":"CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia","volume":"146","author":"Geyer","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026042311314055900_bib8","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41467-022-29668-9","article-title":"Allogeneic TCRalphabeta deficient CAR T-cells targeting CD123 in acute myeloid leukemia","volume":"13","author":"Sugita","year":"2022","journal-title":"Nat Commun"},{"key":"2026042311314055900_bib9","unstructured":"Incorvaia\n              D\n            \n          . Vor Bio to wind down, halting cell therapy trials and shedding most staff. 8 May 2025. Accessed 19 January 2026. https:\/\/www.fiercebiotech.com\/biotech\/cell-therapy-firm-vor-bio-wind-down-halting-trials-and-shedding-staff."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/17\/1889\/2514358\/blood_bld-2026-033164-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/17\/1889\/2514358\/blood_bld-2026-033164-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:31:49Z","timestamp":1776958309000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/17\/1889\/567812\/Donor-T-cells-on-double-duty-VCAR33-for-AML-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":9,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,4,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026033164","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,23]]},"published":{"date-parts":[[2026,4,23]]}}}